ECE2014 Poster Presentations Endocrine tumours and neoplasia (99 abstracts)
Patient-reported outcomes associated with lanreotide Autogel (LAN-ATG) for symptom control of carcinoid syndrome in gastroenteropancreatic neuroendocrine tumour patients: results of SYMNET, a large International Multicentre Observational Study
Philippe Ruszniewski 1 , Martyn Caplin 2 , Juan Valle 3 , Catherine Lombard-Bohas 4 , Graeme Poston 5 , Petros Perros 6 , Lubos Holubec 7 , Gianfranco Delle Fave 8 , Denis Smith 9 , Patricia Niccoli 10 , Pascal Maisonobe 11 & Philippe Atlan 11
1Hôpital Beaujon, Clichy, France; 2Royal Free Hospital, London, UK; 3Christie NHS Foundation Trust, Manchester, UK; 4Hôpital Edouard-Herriot, Lyon, France; 5University Hospital Aintree, Liverpool, UK; 6Freeman Hospital, Newcastle, UK; 7Teaching Hospital Plzen; Plzen–Bory, Czech Republic; 8Ospedale Sant’ Andrea, Rome, Italy; 9Hôpital Saint André, Bordeaux, France; 10CHU Timone, Marseille, France; 11Ipsen, Boulogne-Billancourt, France.
Introduction: Somatostatin analogues are widely used to reduce the incidence and severity of carcinoid syndrome symptoms. However, their impact on patients’ satisfaction with symptom control needs further investigation. SYMNET was a large international multicentre observation study that assessed PROs during LAN-ATG treatment of carcinoid syndrome in gastroenteropancreatic neuroendocrine tumour (GEP–NET) patients.
Methods: At routine clinic visit, patients with diarrhoea related to carcinoid syndrome and receiving LAN-ATG for >3 months were asked to complete PRO questionnaires on satisfaction and symptoms associated with their treatment. Investigators also assessed patients’ medical records to identify patient characteristics that were potential predictors of treatment satisfaction.
Results: Of 273 patients enrolled, 56% were males, 57% were aged >60 years, 66% had small bowel primary tumours, and 80% had liver metastases. Prior to the study, 66% had surgery and 23% other anti-tumour therapy within last 3 months. Mean time since diagnosis was 4.4 years. Mean LAN-ATG treatment duration was 21.7 months and median dose 120 mg/month on study day. Most patients (76%) were satisfied with diarrhoea control, and flushing control (73%). More patients indicated no, minimal, or mild diarrhoea at study visit (75%) than did before treatment (33%). Most (79%) patients reported diarrhoea was improved overall with LAN-ATG. Investigators identified a clinically relevant decrease in stool frequency since treatment initiation (median: 4–2 episodes/day). Statistically significant decreases (McNemar paired tests, P<0.001) were seen in the proportion of patients with urgency (73–41%), leakage (21–9%), and associated pain (37–4%). Predictors of satisfaction with diarrhoea control were initial stool leakage and non-small bowel primary localization.
Conclusions: GEP–NET patients reported favourable symptom control with LAN-ATG treatment. Improvements in PROs were consistent with those on investigators’ medical assessments. Patients’ satisfaction with symptom control on LAN-ATG may be supported by associated factors.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more